Skip to content

13F-HR filed by Merck & Co., Inc.

Merck & Co., Inc. filed this 13F-HR for the quarter ended 2025-12-31, filed 2026-02-17, with 12 holding rows worth $276,276,803.

Accession
0000310158-26-000055
Filed
2026-02-17
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2025

A holdings report, 12 entries on the cover page, a total value of $276,276,803 stated on the cover page (in dollars after the unit check, H1), rows summing to $276,276,803 with VALUE read as dollars as filed, 13F file number 028-25193. The quarter's positions are built on this report. The resolved quarter.

Other managers

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
PERSONALIS INC71535D106COMMON STOCK14,044,943$111,797,746dollars as filed
MODERNA INC60770K107COM2,308,190$68,068,523dollars as filed
KYMERA THERAPEUTICS INC501575104COM772,165$60,082,159dollars as filed
ENTRADA THERAPEUTICS INC29384C908COM1,739,768$17,884,815dollars as filed
EVAXION BIOTECH A/S29970R204SPONSORED ADS1,214,126$5,791,381dollars as filed
ALECTOR INC014442107COMMON STOCK3,545,719$5,531,322dollars as filed
SUTRO BIOPHARMA INC869367102COM272,351$3,151,101dollars as filed
VIRIDIAN THERAPEUTICS INC92790C104COM93,414$2,907,044dollars as filed
Xilio Therapeutics Inc.98422T100COM1,483,758$949,902dollars as filed
CARISMA THERAPEUTICS INC14216R101COM1,473,240$63,349dollars as filed
NEUPHORIA THERAPEUTICS INC64136E102COM10,027$38,905dollars as filed
TUHURA BIOSCIENCES INC898920103COM13,950$10,556dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000310158-26-000055this filing2026-02-17acceptance time not in the bulk data set